Duality Biotherapeutics Inc. (DYBTY)

“The real science in antibody-drug conjugates is not the antibody — it is the linker and the payload, and having the right chemistry for each target.”

This observation captures the essence of why Duality Biotherapeutics exists and what separates the company from broader oncology peers. Antibody-drug conjugates, or ADCs, are a therapeutic category in which a monoclonal antibody (a protein that homes to specific cancer cells) is chemically linked to a highly toxic payload — a drug that kills cells. The elegance of the approach is that the antibody delivers the poison directly to the target, ideally minimizing harm to healthy tissue. The challenge is that the chemistry must be exquisite. The linker connecting antibody to payload must be stable enough not to release the drug before reaching the tumor, yet reactive enough to do so once inside the cell. The payload must be potent enough to work at low doses (since the antibody can only carry a limited amount) and not so broad-spectrum that it damages the antibody’s ability to bind target cells.

Duality Biotherapeutics was founded to build platform chemistry around these problems. Rather than betting the company on a single candidate or pursuing a generic approach, Duality constructed four proprietary ADC platforms — DITAC, DIBAC, DIMAC, and DUPAC — each with different linker and payload characteristics. This platform-based approach offers two advantages. First, it allows the company to rapidly generate multiple candidates from a single target antigen: if one linker-payload combination fails in the clinic, the company can quickly test another without having to invent new chemistry. Second, it creates optionality: different cancer types and different antigens benefit from different chemistry, and having multiple platforms means Duality can match the platform to the biology rather than forcing all candidates into one mold.

The company entered the clinic with a growing roster of candidates. By early 2026, Duality had enrolled over 1,500 patients across multiple clinical trials running in 17 countries. The pipeline includes DB-1305, DB-1311, DB-1419, and DB-1310 among others, with several programs in Phase I and Phase II trials and additional candidates in investigational-new-drug (IND) enabling stages. The targets span multiple cancer types — ovarian, bladder, lung, gastric, and others — and the company has also pursued autoimmune applications, a less-tested but potentially substantial opportunity for ADC technology.

The company’s strategy reflects a fundamental truth about modern oncology: the ADC category is crowded. Multiple large pharma companies have ADC programs; academic labs have published extensively on ADC chemistry; and contract research organizations can now synthesize complex linker-payload combinations relatively cheaply. The barrier to entry has fallen. What Duality is betting is that it can move faster and smarter than larger companies constrained by corporate bureaucracy and can identify binding combinations and target antigens that competitors missed. The platform approach, in theory, gives Duality that velocity.

The company has also positioned itself for partnership or acquisition, a natural path for clinical-stage biotech. Large pharma companies that lack depth in ADC chemistry or antigen discovery can license or acquire Duality’s platforms and fold them into their own clinical-development machine. Several precedents exist: Pfizer acquired a smaller ADC company in 2018; Seagen (before its own acquisition) started as an ADC specialist and eventually partnered with large pharma on development and commercialization. Duality’s platforms may be more valuable as a platform licensed to multiple programs than as a single company developing all programs internally.

Clinical and commercial risks.

The primary risk is clinical failure. Cancer drug development is inherently risky — even well-designed ADCs can fail in the clinic if the biology does not cooperate, if patient populations are misidentified, or if toxicity emerges at relevant doses. Duality’s portfolio approach mitigates some of this risk (one failure does not kill the company), but if multiple programs fail or progress slowly, the company will burn cash without generating near-term revenue, forcing dilutive financing or a desperate partnership on unfavorable terms.

A second risk is competitive intensity. If multiple ADC programs reach the market successfully and become standard-of-care for specific cancers, pricing pressure and market saturation will limit Duality’s ability to commercialize. The company would then face the usual biotech challenge: how to compete as a new entrant against entrenched therapies with established sales forces and prior patient experience.

A third risk is scientific obsolescence. Oncology is moving rapidly toward combination therapies, checkpoint inhibitors, CAR-T cells, and other modalities. An ADC that works brilliantly as a monotherapy but cannot be easily combined with other approaches may have limited clinical utility and market opportunity, even if it reaches approval.

How to monitor Duality as a public company.

Once Duality is public, track clinical trial enrollment and advancement. Enrollment that is slower than planned or data readouts that show unanticipated toxicity are red flags. Watch for any partnerships or in-licensing deals: any agreement to develop Duality’s platforms across new indications or geographies is a validation signal and a potential revenue stream.

Monitor burn rate — how much cash the company is spending monthly — and the runway to profitability. Clinical biotech companies burn cash for years before a drug reaches market, and the runway number tells you how much time Duality has before it must achieve a meaningful milestone (or seek partnership) to justify further investment. Follow clinical-trial presentations at major oncology conferences such as ASCO and ESMO; these are where the most transparent data emerges. Any major competitive ADC approvals should prompt analysis of how Duality’s candidates compare — are they in less-crowded indications, do they have less toxicity, are they easier to manufacture? Finally, watch shareholder communications from management for any signals about partnership discussions or financing plans. Clinical-stage biotech can move quickly, and announcements of partnerships, licensing deals, or major financing rounds often correlate with inflection points in value.